Indian pharmaceutical companies are expected to report improved revenues in the first quarter of FY2026-27, but profitability is likely to come under pressure due to an unfavourable product mix and higher input costs, according to a report by Goldman Sachs.
In its Q1FY27 preview, the brokerage said revenues are expected to improve, but margins are likely to decline as companies no longer benefit from high-margin while facing higher raw material and freight costs arising from the Middle East conflict.
